AGM Statement

Summary by AI BETAClose X

CRISM Therapeutics' AGM statement highlights key achievements since its AIM admission in May 2024. A Clinical Trial Authorisation application was submitted to the MHRA in June for a Phase 2 study of irinotecan ChemoSeed in glioblastoma patients. Production of a clinical batch of ChemoSeed under Good Manufacturing Practice has commenced. The company successfully raised £874,021 in June through a recent fundraise. Innovate UK awarded a grant to support pre-clinical development of ChemoSeed for prostate cancer. The company is focused on gaining trial approval from the MHRA in glioblastoma and progressing towards dosing first patients in early 2026.

Disclaimer*

UK 100

Latest directors dealings